Kornimate/medical-research-clean huggingface dataset:
the effect of kiwi on blood pressure, endothelial function, antioxidant capacity and gene expression

Conditions: Hypertension

Summary: the purpose of this study is to determine whether the intake of kiwi fruits will reduce systolic and diastolic blood pressure compared to intake of apples. the investigators hypothesize that the increased intake lutein or other components in the kiwi fruit will enhance nitric oxide bioavailability and lead to vascular relaxation.

an interesting finding in the oslo antioxidant study was that intake of 3 kiwi fruits reduced blood pressure in a clinical significant manner compared to controls. the mechanism for the blood pressure reducing effect of kiwi or the responsible components are not elucidated. however, plasma lutein levels and antioxidant capacity measured by the ferric reducing antioxidant power was increased in the kiwi group. moreover, gene expression was also altered by the increased intake of kiwi.

Eligibility criteria:
inclusion criteria: * systolic blood pressure 130-159 mmhg * diastolic blood pressure 85-99 mmhg * body mass index \<35 kg/m2 exclusion criteria: * systolic blood pressure \>160 mmhg or \<129 mmhg * diastolic blood pressure \>100 mmhg or \<84 mmhg * current use or need for blood pressure lowering medication * symptomatic cardiovascular disease, diabetes, renal dysfunction, psychiatric disorder, pregnancy or lactation, history of obesity surgery.

Keywords: kiwi fruits blood pressure endothelial function antioxidant capacity
impact of pulmonary rehabilitation on loneliness in copd

Conditions: Loneliness

Summary: loneliness is the feeling of sadness because one wants friends or company. this feeling is common in patients with chronic lung disease, who suffer from breathing difficulty, chronic cough, and reduced physical and mental health. these problems lead to a reduced ability for doing daily activities and cause a loss of social life. pulmonary rehabilitation (pr) includes exercise and education. pr has been shown to improve health status in patients with chronic lung disease but its impact on loneliness levels has never been assessed. this study aims to assess the effect of pr on reducing loneliness in patients with chronic lung disease.

pulmonary rehabilitation (pr), composed of exercise training, education, and self-management strategies, is the standard of care for managing individuals with chronic obstructive pulmonary disease (copd). pr improves dyspnea, functional exercise capacity, health-related quality of life and decreases hospitalizations and mortality. regular exercise has been shown to reduce loneliness in older adults and those with chronic conditions, in association with a reduction in pain, the development of friendly relationships and enhanced psychological well-being. however, there is limited information regarding the impact of pr on the level of loneliness in individuals with copd. study purpose the purpose of this study is to examine the effect of pr on loneliness levels in individuals with copd and to examine the relationship between changes in loneliness and changes in exercise capacity, health-related quality of life, depression, and anxiety levels. this pre-post interventional study will be conducted at the west park healthcare centre and st. joseph's healthcare hamilton. ethics approval will be obtained from the joint west park healthcare centre - the salvation army toronto grace health centre research ethics board (jreb) and the hamilton integrated research ethics board (hireb). participants based on mimi et al. (2014), a sample size of 45 participants is required to detect minimal significant effects on the university of california \& los-angeles loneliness scale (ucla-ls), with 80% power (α= 0.05, β= 0.20) and assuming a drop-out rate of 25%. the sample will include male and female individuals who have been diagnosed with copd.

Eligibility criteria:
inclusion criteria: * a spirometry (fev1/fvc \< 0.70) or physician-confirmed diagnosis of copd * aged 18 years or more * ability to complete at least 60% of the pr program that includes exercise, education, and behaviour change intervention * ability to provide written informed consent. abbreviations: fev1: forced expiratory volume in 1 second fvc: forced vital capacity exclusion criteria: * do not have sufficient language skills (non-english speaking or reduced cognition) * are unable to complete at least 60% of pr * fail to complete the primary outcome measure, the university of california, and los angeles loneliness scale (ucla-ls).
high dose oral omeprazole in high risk ugib

Conditions: GI Bleeding

Summary: peptic ulcer bleeding is the most common etiology in upper gastrointestinal bleeding all over the world. after endoscopic treatment, proton pump inhibitor (ppi) is recommended to prevent re-bleeding. intravenous ppi is recommended as a standard treatment.in the past, there were many trials showing the efficacy of high-dose oral ppi after endoscopic hemostasis but most were industrial sponsor which assessing an expensive ppi. moreover, the number of patients in those studies were insufficient to confirm a non-inferiority outcome in term of rebleeding by using oral ppi. this study will evaluate a high-dose, local-made ppi (omeprazole) in peptic ulcer treatment after successful endoscopic hemostasis compared to standard iv ppi continuous drip.


Eligibility criteria:
inclusion criteria: * patients with peptic ulcer bleeding and endoscopic finding show ulcer with forrest classification ia (spurting haemorrhage), iia (oozing haemorrhage), ib (non-bleeding visible vessel) * age \> 18 years old exclusion criteria: * deny to participate * pregnancy or lactation * low risk peptic ulcer bleeding including clean base ulcer, flat pigmented spot * non-peptic ulcer bleeding eg. erosive gastritis/duodenitis, mallory weiss tear, esophageal/gastric/duodenal varices, vascular lesions (eg. dieulafoy) , malignant ulcer * bleeding tendency * terminal stage of cancer * esrd on hemodialysis * decompensated liver cirrhosis

Keywords: oral proton pump inhibitor
jeti hong kong post market study (pms)

Conditions: Peripheral Venous Thrombosis; Peripheral Arterial Thrombosis; Peripheral Arteriovenous Thrombosis

Summary: the jeti hong kong pms is a single-arm, multicenter study to collect real-world data on the safety, performance, and clinical benefits of the jeti system for the treatment of acute and subacute thrombosis in the peripheral vasculature. this is a post-market study that will register approximately 20 subjects at approximately 5 centers in hong kong. subjects participating in this study will be followed for up to 30 days (in cases of prospective consent) after day 0. day 0 is defined as the day when the jeti catheter is introduced into the intended vasculature of the subject.

the jeti system is a hydro-mechanical aspiration system manufactured by abbott medical, consisting of a catheter, pump set, and accessories. the system is intended to remove/aspirate fluid and break-up soft emboli and thrombus from the peripheral vasculature and to subselectively infuse/deliver diagnostics or therapeutics with or without vessel occlusion. this study will collect data on how the jeti system performs in the treatment of patients undergoing a percutaneous thrombectomy procedure for peripheral thrombosis. subjects treated for arterial, venous, or arteriovenous thromboses, and subject with diagnoses such as acute limb ischemia (ali), chronic limb ischemia/chronic limb threatening ischemia (cli/ctli), peripheral artery disease (pad), deep vein thrombosis (dvt), hemodialysis access thrombosis, and others may be included. both prospective and retrospective consent (if all assessments needed for the primary endpoints are complete) are permitted. after index procedure, subjects will be evaluated at discharge and 30 days in cases of prospective consent. in cases of retrospective consent, duration of participation will vary. if consent occurs after the procedure and prior to 30 days, the subject will be asked to return for a 30-day visit. if consent occurs after 30 days, the subject will not need to return for a study visit. relevant data will be collected from the medical record.

Eligibility criteria:
inclusion criteria: 1. subject was treated or is expected to be treated for acute/subacute thrombosis, as determined by investigator, in the peripheral vasculature with the jeti hydrodynamic thrombectomy system. 2. subject or legally authorized representative must provide written informed consent 3. subject must be ≥ 18 years of age and of asian race. exclusion criteria: 1. subject has previously been registered in the jeti hong kong pms in the last 12 months unless treated in the contralateral limb/different anatomy; patients treated in the contralateral limb/different anatomy within the last 12 months may re-enroll in the study. 2. subject is currently participating in another drug or device clinical investigation. 3. subject has active symptoms and/or a positive test result of covid-19 or other rapidly spreading infectious agent within the past 20 days.
thickness of retinal layers in amblyopia

Conditions: Amblyopia

Summary: the purpose of this study is to examine retinal layer thickness in amblyopia.

amblyopia is a visual disorder characterized by a reduction of vision that cannot be immediately improved by refractive correction or accounted for by clinically determined anatomic defects of the eye or visual pathway. evidence for direct retinal changes in eyes with amblyopia has been controversial. it has been hypothesized that amblyopia may affect the postnatal maturation of the retina including the postnatal reduction of retinal ganglion cells. however, although some studies have found incrased retinal nerve fiber layer thickness in amblyopic eyes, others have found no significant differences. this sutdy will examine the retinal layer thickness in amblyopia and compare the retinal layer thickness between amblyopic eyes and nonamblyopic fellow eyes.

Eligibility criteria:
inclusion criteria: * amblyopia exclusion criteria: * other retinal disease * anisometropia * neurologic abnormalities

Keywords: amblyopia retinal layer thickness
entrust, a 5 year surveillance of children aged 2 to <6 years with transfusional iron overload treated with deferasirox

Conditions: Anemia

Summary: this registry will evaluate long-term safety and efficacy of deferasirox in children with transfusional iron overload.


Eligibility criteria:
inclusion criteria: * history of transfusion-dependent anemia. * history of iron overload exclusion criteria: * patients with non-transfusional hemosiderosis. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: iron overload children deferasirox transfusion-dependent anemia
changes on pain and range of motion by the use of kinesio taping in subjects with myofascial trigger point

Conditions: Mobility Limitation; Myofascial Trigger Point Pain

Summary: the aim of this study is to demonstrate that the application of kinesio taping on a myofascial trigger point in the trapezius muscle able to cause a decrease of the trigger point pain and an increase of the cervical range of motion in asymptomatic subjects

the use of kinesio taping has become very popular for the treatment of many musculoskeletal disorders in recent decades. of the six variants of application that has the kinesio taping, the space correction technique is suggested for pain management. the increased space achieved with this variant decreases the pressure kinesio taping by raising the skin directly over the treatment area, reducing chemical irritation receptors and therefore pain. the aim of this study is to demonstrate that the application of this variant of kinesio taping on a myofascial trigger point in the trapezius muscle able to cause a decrease of the pain and an increase of the cervical range of motion in asymptomatic subjects. for this, the pressure pain threshold will be measured with a algometer on the trigger point and the range of motion with a cervical goniometer.

Eligibility criteria:
inclusion criteria: * agree to participate in the study (signed informed consent) * presence of latent myofascial trigger point in upper trapezius. exclusion criteria: * subjects in which not clearly identified myofascial trigger point in the upper trapezius . * subjects who suffer or have suffered pathologies of upper limb deformities or orthopedic injuries that can alter static and biomechanics of shoulder and neck. * subjects who suffer or have suffered rheumatic or neurological disease or chronic shoulder pain and/or neck * subjects diagnosed with fibromyalgia, myelopathy or radiculopathy. * subjects suffering from any psychiatric disorder (such as anxiety or depression). * subjects who have suffered post-traumatic alteration (whiplash type) or cervical surgery. * pregnancy risk of abortion. * have used analgesics in the 48 hours before participating in the study * subjects presenting any contraindications to the application of kinesio taping. * know the kinesio taping technique applied in the study. * be receiving physical therapy for any shoulder or neck pathology.
stereotactic management of arrhythmia - radiosurgery in treatment of ventricular tachycardia

Conditions: Ventricular Tachycardia

Summary: prospective single-arm study investigating the safety of non-invasive cardiac radiosurgery for the treatment of ventricular tachycardia (vt).

the standard of care for the treatment of ventricular tachycardia (vt) comprises of pharmacotherapy, icd implantation and electrophysiology-guided catheter ablation. the treatment, however, is associated with a relatively high risk of vt recurrence. given the limited therapeutic options and significant impact on patients quality of life, non-invasive cardiac radiosurgery has been recently gaining popularity in scientific literature as a viable alternative to salvage catheter ablations. considering the scarcity of data from prospective trials and concern about the safety of the treatment method, this trial seeks to determine whether stereotactic management of arrhythmia - radiosurgery in treatment of ventricular tachycardia (smart-vt) meets the expected safety requirements for clinical use.

Eligibility criteria:
inclusion criteria: * patients with structural heart disease and implantable cardioverter defibrillator (icd) * clinically significant arrhythmia with at least 3 vt episodes per month despite adequate pharmacological treatment. * at least one episode of monomorphic vt registered in electrophysiological examination. * recurrent vt despite at least one prior catheter ablation and adequate pharmacotherapy or contraindications to catheter ablation and/or pharmacotherapy (i.e., patient with medically contraindicated catheter ablation is obliged to undergo only pharmacotherapy prior to study enrollment). * patient must be able to understand and be willing to sign a written informed consent document. exclusion criteria: * heart failure requiring inotropic treatment or mechanical assistance * arrhythmia due to cardiac channelopathy * reversible source of arrhythmia * nyha (new york heart association) stage iv hearth failure * hearth infarction or cardiac surgery in last 3 months * life expectancy \<6 months * polymorphic vt * pregnancy * prior radiotherapy to the thoracic region (relative contraindication) * failure to induce vt during electrophysiological examination

Keywords: ventricular tachycardia ablation noninvasive stereotactic body radiation therapy radiosurgery substrate ablation
large sample pd patients and healthy controls

Conditions: Neuro-Degenerative Disease

Summary: resting-state functional magnetic resonance imaging (rs-fmri) has frequently been used to investigate local spontaneous brain activity in parkinson's disease (pd) in a whole-brain, voxel-wise manner. to quantitatively integrate these studies, we conducted a coordinate-based meta-analysis on 15 studies that used amplitude of low frequency fluctuation (alff) and 11 studies that used regional homogeneity (reho). all these alff and reho studies have compared pd patients with healthy controls. we also performed a validation rs-fmri study of alff and reho in a frequency-dependent manner for a novel dataset consisting of pd and healthy controls.

seed-based d mapping (formerly signed differential mapping, sdm) software (version 5.141 for windows) (www.sdmproject.com) was used for meta-analysis. for the validation, fmri data were acquired on a 3 tesla magnetic resonance scanner (trio system; siemens magnetom scanner, erlangen, germany) with gradient-echo echo-plannar imaging sequences. whole brain fmri scanning was carried out. all participants were instructed to keep their eyes closed, relax, remain motionless, not think of anything in particular, and not fall asleep. foam pads were used to minimize head motion.

Eligibility criteria:
inclusion criteria: * the pd diagnoses were based on the uk parkinson's disease society brain bank clinical diagnostic criteria. patients were assessed using the updrs iii and hoehn and yahr disability scale. exclusion criteria: * 1. history of head trauma, 2. substance abuse, 3. psychiatric disorder. for healthy controls, additional exclusion criteria included 1. any history of neuropsychiatric disorders.
pathogens responsible for respiratory infections associated with drowning in seawater

Conditions: Drowning

Summary: little data is currently available on the type of pathogen responsible for respiratory infections following drowning. many environmental germs present in seawater are described as difficult to culture on standard media but are potentially pathogenic. even using specific culture media nearly 90% of the bacteria present in the water remain non-cultivable. the use of 16s and 18s rdna amplification followed by high throughput sequencing on respiratory samples could allow us to objectify these bacteria potentially involved in the physiopathological process secondary to drowning and thus improve their overall management. carrying out a bronchoalveolar lavage (bal) within 24 hours after admission to intensive care with analysis on standard and specific culture media of environmental germs, carrying out antibiograms, dna extraction, amplification by universal 16 and 18s rdna primers followed by high flow sequencing and phylogenetic analysis of pathogens found. comparison of these results with the same analyses performed on seawater samples taken near the drowning site and during a new aml at 72h for patients still intubated and showing signs of pneumonia in order to determine if the pathogens detected at the entrance persist and are present in the environment. aml at the patient's entrance, on day 3 and environmental sampling in the drowning environment within 24 hours. standard and specific bacteriological analyses with molecular biology techniques (amplification 16 and 18s rdna) carried out at pr ruimy's laboratory (nice university hospital) sequencing on inra's toulouse genomics platform. phylogenetic data capture and analysis at ircan (bioinformatics, croce olivier). patient follow-up until resuscitation discharge.


Eligibility criteria:
inclusion criteria: * adult patient * hospitalized in intensive care for severe drowning in sea water (spilzman stage 5 or 6) (4) * intubated within 24 hours of admission or before admission to intensive care * affiliated to social security exclusion criteria: * patients under guardianship, trusteeship or detention
safety and efficacy study of ipx159 in restless legs syndrome (rls)

Conditions: Restless Legs Syndrome

Summary: the purpose of this study is to determine whether ipx159 is safe and effective in treating symptoms of rls in subjects with restless legs syndrome.

ipx159 was developed as an extended release formulation to reduce the fluctuation in nefopam concentration compared to ir and to reduce the incidence of peak or rate related side effects.

Eligibility criteria:
inclusion criteria: 1. able to understand and willing to sign an informed consent form (icf) and health insurance portability and accountability act (hipaa) authorization 2. males and females aged 18-70 with a history of primary rls for ≥6 months prior to screening 3. symptoms of rls by medical history on at least 15 nights during the month prior to screening 4. bmi 18.5-32 5. negative alcohol and drug abuse screen 6. negative serum pregnancy test 7. agrees to use a medically acceptable method of contraception throughout the study and for 2 months after completing the study. 8. able and willing to comply with the protocol, including availability for all scheduled clinic visits and telephone calls. exclusion criteria: 1. subjects who use or intend to use post screening the following medications or medication categories: * sedative hypnotics, trazodone * dopamine agonists, gabapentin, gabapentin enacarbil, pregabalin * narcotic analgesics, other opioids, tramadol, cyclobenzaprine * iron supplementation therapy 2. history of hiv, hepatitis b or c 3. pregnant or breastfeeding. 4. history of or clinical signs of any form of epilepsy or seizures, excluding fever-related seizures in childhood. 5. history or presence of glaucoma 6. planning to take herbal medications (eg, hypericum perforatum \[st john's wort\], licorice, ephedra, ginkgo, ginseng) during the study. 7. use of any investigational drug within the last 30 days or within a period of 5 times the drug's half-life, whichever is longer 8. subjects who, in the opinion of the investigator, should not participate in the study or are not capable of following the study schedule for any reason 9. employees or family members of the investigator, study site, the sponsor, or contract research organization (if any)

Keywords: moderate to severe idiopathic rls